Lurbinectedin is a novel anticancer drug that is currently being investigated for its efficacy in treating various types of cancers, including breast cancer. Lurbinectedin is a synthetic analog of the marine compound trabectedin, which is derived from the tunicate Ecteinascidia turbinata. Lurbinectedin targets cancer cells by binding to the DNA molecule and interfering with the transcription process [1].

In breast cancer cells, lurbinectedin has been shown to specifically target the transcription factor FOSL1, which is known to be overexpressed in many types of cancer, including breast cancer. FOSL1 is a key regulator of cancer cell proliferation, migration, and invasion, and its inhibition has been shown to induce cancer cell death [2].

A recent study published in Molecular Cancer Therapeutics investigated the mechanism of action of lurbinectedin in breast cancer cells. The study found that lurbinectedin specifically triggers the degradation of FOSL1 protein in breast cancer cells, leading to a decrease in cancer cell proliferation and an increase in cancer cell death [3].

In conclusion, lurbinectedin targets breast cancer cells by binding to the DNA molecule and interfering with the transcription process. Specifically, lurbinectedin targets the transcription factor FOSL1, which is overexpressed in many types of cancer, including breast cancer. Lurbinectedin triggers the degradation of FOSL1 protein in breast cancer cells, leading to a decrease in cancer cell proliferation and an increase in cancer cell death [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://aacrjournals.org/mct/article/15/10/2399/92096/Lurbinectedin-Specifically-Triggers-the.